VIP (Vasoactive Intestinal Peptide) Dosing & Reconstitution Guide

VIP can be administered via intranasal or subcutaneous routes, with the choice often depending on the specific research protocol being followed. Studies indicate that doses typically range from 50 to 100 mcg when administered intranasally, while intravenous dosing may exceed these amounts in clinical settings. The duration of treatment cycles can vary significantly, with typical lengths for Chronic Inflammatory Response Syndrome (CIRS) protocols ranging from 30 to 90 days. Research applications may necessitate different cycle lengths based on experimental design. Furthermore, morning administration is frequently utilized to align with circadian rhythms, though this may vary based on individual study parameters. It is essential to approach dosing with caution, recognizing the variability in individual responses and the potential for dose-related effects.

The stability of VIP is critically dependent on its storage conditions. In its lyophilized form, VIP should be maintained at -20°C to preserve its integrity, as it is a highly fragile peptide susceptible to degradation. Once reconstituted, VIP should be stored between 2-8°C and used within a maximum of 7-14 days due to its rapid degradation profile. This limited stability underscores the importance of careful handling and timely use in experimental setups to ensure reliable results. Researchers are encouraged to monitor storage conditions closely to mitigate the risk of degradation and ensure the peptide's effectiveness in their studies.

Research indicates that VIP has a very short plasma half-life of approximately 1-2 minutes, which restricts its systemic effects and necessitates continuous infusion in certain applications. The primary dose-limiting adverse effect associated with VIP administration is hypotension, attributable to its potent vasodilatory properties. Additional side effects such as diarrhea and flushing have been reported at higher doses, aligning with the known physiological effects of VIP. Contraindications for VIP use include severe hypotension or hemodynamic instability, as well as the presence of VIPoma or VIP-secreting tumors, which could exacerbate symptoms. Furthermore, due to a lack of adequate safety data, VIP is contraindicated in pregnant and breastfeeding individuals. Understanding these safety considerations is vital for researchers to minimize risks in experimental contexts.